Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Deoxycholic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 known ✓ | Q96RI1 | 5/20 | 0.83 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.83 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.83 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.83 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.78 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.78 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.78 |
| ▸ | CASP7 | P55210 | 3/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxycholic Acid SCHEMBL246888 | 1.00 | GPBAR1 (0.83) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| Cholic Acid SCHEMBL1758945 | 0.98 | GPBAR1 (0.82) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| Deoxycholic Acid SCHEMBL16055173 | 0.95 | GPBAR1 (0.75) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| Cholic Acid SCHEMBL2467584 | 0.95 | GPBAR1 (0.85) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| Cholic Acid SCHEMBL2637799 | 0.95 | GPBAR1 (0.88) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| Deoxycholic Acid SCHEMBL2323977 | 0.93 | GPBAR1 (0.93) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL7546767 | 0.93 | GPBAR1 (0.71) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL2369521 | 0.93 | GPBAR1 (0.71) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| Cholic Acid SCHEMBL1287856 | 0.92 | GPBAR1 (0.93) | GPBAR1NR1H4SLC10A2PDE3ACYP3A4 | |
| Chenodiol SCHEMBL2638869 | 0.92 | GPBAR1 (0.89) | GPBAR1NR1H4SLC10A2CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076292-A9 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | Satellite Biosciences, Inc. (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023076292-A1 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | Satellite Biosciences, Inc. (US) | 2023-05-04 | — | — | WO | claimed |
| US-11530388-B2 | Methods of engineering human induced pluripotent stem cells to produce liver tissue | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-12-20 | — | — | US | claimed |
| US-20240000803-A1 | ORAL FORMULATION OF BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | D&D PHARMATECH INC. (KR) | 2024-01-04 | — | — | US | disclosed |
| EP-4252781-A1 | ORAL FORMULATION OF BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | D&D Pharmatech Inc. (KR) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023076292-A9 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | Satellite Biosciences, Inc. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023076292-A1 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | Satellite Biosciences, Inc. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11530388-B2 | Methods of engineering human induced pluripotent stem cells to produce liver tissue | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2021060127-A1 | LIPOPOLYSACCHARIDE PRODUCTION METHOD | 有限会社バイオメディカルリサーチグループ | 2021-04-01 | — | — | WO | disclosed |
| EP-1259532-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | Bracco Imaging S.p.A. (IT) | 2002-11-27 | — | — | EP | disclosed |
| EP-1210359-A2 | A PROCESS FOR THE PREPARATION OF 3-AMINO BILE ACID DERIVATIVES | BRACCO IMAGING S.p.A. (IT) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001064708-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING S.P.A. (IT) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001016157-A2 | A PROCESS FOR THE PREPARATION OF 3-AMINO BILE ACID DERIVATIVES | BRACCO IMAGING S.P.A. (IT) | 2001-03-08 | — | — | WO | disclosed |
| EP-0760683-A1 | BILE ACID CONJUGATES, DERIVATIVES THEREOF WITH METAL COMPLEXES AND RELATED USES | BRACCO S.p.A. (IT) | 1997-03-12 | — | — | EP | disclosed |
| WO-1995032741-A1 | BILE ACID CONJUGATES, DERIVATIVES THEREOF WITH METAL COMPLEXES AND RELATED USES | BRACCO S.P.A. (IT) | 1995-12-07 | — | — | WO | disclosed |
| EP-0462071-B1 | Pharmaceutical resorption-improved somatostatin compositions, their preparation and use | SANDOZ LTD (CH) | 1995-02-01 | — | — | EP | disclosed |
| EP-0462071-A1 | Pharmaceutical resorption-improved somatostatin compositions, their preparation and use | SANDOZ LTD. (CH) | 1991-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000803-A1 | ORAL FORMULATION OF BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | FABP2, FABP1, ALOX15B | NR1H4 239/4885GPBAR1 209/4885SLC10A2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.